Quansys Biosciences releases multiplex assay to measure antibodies from vaccination and from natural infection

Logan, UT, July 28, 2021 – Quansys Biosciences in Logan, Utah, has recently released their Q-Plex™ Human SARS-CoV-2 IgG (5-plex) multiplex ELISA to quantitatively measure antibodies specific to SARS-CoV-2, the novel coronavirus responsible for the global pandemic.

As new variants of SARS-CoV-2 arise, the global response must change and adapt. Tracking the infection and our immune response towards it becomes increasingly important. The available FDA-approved vaccines elicit an immune response towards the spike glycoproteins S1 and S2, which complicates efforts to track natural infection rates as many tests measure those same antibodies.

To aid researchers studying the virus, Quansys has recently introduced the new Q-Plex Human SARS-CoV-2 IgG (5-Plex), which detects antibodies specific for the nucleocapsid in addition to S1 and S2. This allows researchers to distinguish between antibodies gained through vaccination and those that arose against natural infection.

The Q-Plex Human SARS-CoV-2 IgG (5-Plex) is available in a 96-well plate format that follows traditional ELISA protocols, allowing rapid adoption by laboratories.

About Quansys Biosciences

Quansys Biosciences develops and manufactures multiplex ELISA kits that help researchers, vaccine and drug developers, and government agencies learn more about inflammatory responses and disease states. The company was founded in 2005 and are experts at developing multiplex immunoassays. For more information on the assay, visit www.quansysbio.com.